Showing results 1 to 20 of 78
next >
| Issue Date | Title | Author(s) |
| 2015 | 4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass | Chang, Lung-Ji; Dong, Lujia; Zhu, Jun; Ying, Zhitao; Kuo, Hao-Hsian; Liu, Yuchen; Song, Yu-Qin; Wang, Xiao-Pei; Jia, Yong-Qian; Niu, Ting; Liu, Ting; Pan, Ling; Liu, Zhuo-Gang; Li, Tong; Li, Ying-Chun; Yao, Kun; Ke, Xiaoyan; Jing, Hongmei; Bao, Fang |
| 2015 | 4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass | Chang, Lung-Ji; Dong, Lujia; Zhu, Jun; Ying, Zhitao; Kuo, Hao-Hsian; Liu, Yuchen; Song, Yu-Qin; Wang, Xiao-Pei; Jia, Yong-Qian; Niu, Ting; Liu, Ting; Pan, Ling; Liu, Zhuo-Gang; Li, Tong; Li, Ying-Chun; Yao, Kun; Ke, Xiaoyan; Jing, Hongmei; Bao, Fang |
| 2015 | B7-H3 Silencing By RNAi Inhibits Tumor Progression and Enhances Chemosensitivity in U937 Cells | Zhang, Wei; Wang, Jing; Wang, Yanfang; Dong, Fei; Zhu, Mingxia; Wan, Wenli; Li, Haishen; Wu, Feifei; Yan, Xinxing; Yang, Xiao-Feng; Ke, Xiaoyan |
| 2015 | B7-H3 Silencing By RNAi Inhibits Tumor Progression and Enhances Chemosensitivity in U937 Cells | Zhang, Wei; Wang, Jing; Wang, Yanfang; Dong, Fei; Zhu, Mingxia; Wan, Wenli; Li, Haishen; Wu, Feifei; Yan, Xinxing; Yang, Xiao-Feng; Ke, Xiaoyan |
| Feb-2021 | B7-H6 is a new potential biomarker and therapeutic target of T-lymphoblastic lymphoma | Yuan, Lei; Sun, Lu; Yang, Siyuan; Chen, Xin; Wang, Jing; Jing, Hongmei; Zhao, Yu; Ke, Xiaoyan |
| 2020 | B7-H6 Promotes Cell Proliferation, Migration and Invasion of Non-Hodgkin Lymphoma via Ras/MEK/ERK Pathway Based on Quantitative Phosphoproteomics Data | Yang, Siyuan; Yuan, Lei; Wang, Yanfang; Zhu, Mingxia; Wang, Jing; Ke, Xiaoyan |
| 2018 | Biological and clinical influences of NPM1 in acute myeloid leukemia patients with DNMT3A mutations | Yang, Xinrui; Shi, Jinlong; Zhang, Xinpei; Zhang, Gaoqi; Zhang, Jilei; Yang, Siyuan; Wang, Jing; Ke, Xiaoyan; Fu, Lin |
| Mar-2023 | Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53 | Gao, Fan; Hu, Kai; Zheng, Peihao; Shi, Hui; Ke, Xiaoyan |
| Oct-2021 | Circularly permuted TRAIL (CPT) combined with Thalidomide and Dexamethasone in patients with relapsed/refractory Multiple Myeloma: a randomized, double-blind, placebo-controlled phase 3 study | Chen, Wenming; Xia, Zhongjun; Fang, Baijun; Fu, Chengcheng; Li, Wei; Yang, Linhua; Ke, Xiaoyan; Jiang, Hua; Weng, Jianyu; Liu, Li; Zhao, Yaozhong; Zhang, Xuejun; Liu, Aichun; Huang, Zhongxia; Shi, Qingzhi; Gao, Yuhuan; Chen, Xiequn; Pan, Ling; Cai, Zhen; Wang, Zhao; Wang, Yafei; Zhang, Yizhuo; Fan, Yaqun; Hou, Ming; Yang, Shifang |
| 2012 | Circularly Permuted TRAIL (CPT) combined with Thalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma: An Open-Label, Multicenter Phase II Clinical Trial. | Chen, Wenming; Hou, Jian; Zhao, Yaozhong; Qiu, Lugui; Ke, Xiaoyan; Wang, Zhao; Leng, Yun; Jing, Hongmei; Xi, Hao; Zheng, Xiangjun; Wang, Fuxu; Zhu, Bing; Yang, Shifang |
| 2017 | Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study | Leng, Yun; Hou, Jian; Jin, Jie; Zhang, Mei; Ke, Xiaoyan; Jiang, Bin; Pan, Ling; Yang, Linhua; Zhou, Fang; Wang, Jianmin; Wang, Zhao; Liu, Li; Li, Wei; Shen, Zhixiang; Qiu, Lugui; Chang, Naibai; Li, Jianyong; Liu, Jing; Pang, Hongyan; Meng, Haitao; Wei, Peng; Jiang, Hua; Liu, Yan; Zheng, Xiangjun; Yang, Shifang; Chen, Wenming |
| 2018 | Clinical and biological implications of IDH1/2 in acute myeloid leukemia with DNMT3A(mut) | Zhang, Xinpei; Shi, Jinlong; Zhang, Jilei; Yang, Xinrui; Zhang, Gaoqi; Yang, Siyuan; Wang, Jing; Ke, Xiaoyan; Fu, Lin |
| 2010 | Clinical characteristics and prognostic analysis of Chinese patients with diffuse large B-cell lymphoma | Ke, Xiaoyan; Wang, Jing; Gao, Zifen; Zhao, Lingzhi; Li, Min; Jing, Hongmei; Wang, Jijun; Zhao, Wei; Gilbert, Heather; Yang, Xiao-Feng |
| Aug-2022 | Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthere (R)) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial | Shi, Yuankai; Zhang, Qingyuan; Hong, Xiaonan; Wang, Zhen; Gao, Yuhuan; Zou, Liqun; Cen, Hong; Gui, Lin; Li, Yufu; Feng, Jifeng; Wang, Zhao; Zhang, Mingzhi; Jin, Chuan; Zhang, Weihua; Hu, Jianda; Zheng, Chengyun; Zheng, Zhendong; Zhang, Liling; Chen, Shaoshui; Huang, Yunhong; Tang, Yun; Gao, Yajie; Hao, Miaowang; Li, Xiaoling; Chang, Chunkang; Yang, Haiyan; Wu, Hui; Shen, Lida; Ke, Xiaoyan; Zhang, Liangming; Xi, Yaming; Yang, Linhua; Xie, Liangzhi; Gai, Wenlin; Ji, Yanan |
| 2018 | Comparison of spatial chromosomal organization between bone marrow and peripheral blood in acute myeloid leukemia | Tian, Xueli; Wang, Yanfang; Liu, Yu; Yin, Jun; Chen, Dieyan; Ke, Xiaoyan; Ma, Wanyun |
| 2017 | CYFIP1 is a potential tumor suppressor in human diffuse large B-cell lymphoma | Liu, Xi; Xu, Keman; Wang, Jing; Wang, Yanfang; Fu, Lin; Ke, Xiaoyan |
| 25-Apr-2024 | Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study | Shi, Hui; Yang, Fan; Cao, Miaomiao; Xu, Teng; Zheng, Peihao; Guo, Yuelu; Su, Guoai; Feng, Shaomei; Li, Ruiting; Liu, Rui; Liu, Haidi; Ma, Lixia; Ke, Xiaoyan; Hu, Kai |
| 2019 | Dysregulation of N-6-methyladenosine regulators predicts poor patient survival in mantle cell lymphoma | Zhang, Weilong; He, Xue; Hu, Jing; Yang, Ping; Liu, Cuiling; Wang, Jing; An, Ran; Zhen, Jingfei; Pang, Meng; Hu, Kai; Ke, Xiaoyan; Zhang, Xiuru; Jing, Hongmei |
| 2014 | Effect of Eltrombopag on Platelet Response and Safety Results in Chinese Adults with Chronic ITP-Primary Result of a Phase III Study | Yang, Renchi; Hou, Ming; Li, Junmin; Jin, Jie; Huang, Meijuan; Yu, Ziqiang; Xu, Xiaojun; Zhang, Xiaohui; Du, Xin; Niu, Ting; Ke, Xiaoyan; Wang, Jianmin; Liu, Jing; Sun, Jing; Zhao, Yongqiang; Lu, Hua; Guo, Haiyi; Hsu, Belinda |
| Aug-2020 | The efficacy and safety of Geptanolimab (GB226) in patients with relapsed/refractory peripheral T cell lymphoma (PTCL): A multicenter, open-label, single-arm, phase 2 trial | Shi, Yuankai; Wu, Jianqiu; Wang, Zhen; Zhang, Liling; Wang, Zhao; Zhang, Mingzhi; Cen, Hong; Peng, Zhigang; Li, Yufu; Fan, Lei; Guo, Ye; Ma, Liping; Cui, Jie; Gao, Yuhuan; Yang, Haiyan; Zhang, Hongyu; Wang, Lin; Zhang, Weihua; Zhang, Huilai; Xie, Liping; Jiang, Ming; Zhou, Hui; Shuang, Yuerong; Su, Hang; Ke, Xiaoyan; Jin, Chuan; Du, Xin; Du, Xin; Liu, Li; Xi, Yaming; Ge, Zheng; Feng, Ru; Zhang, Yang; Zhou, Shengyu; Xie, Fan; Gao, Chao |
